Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $15 from $11 and keeps a Neutral rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes announces t:slim X2 insulin pump cleared for use in U.S.
- Leerink says removal of C-peptide requirement would benefit pump market, Tandem
- Tandem Diabetes announces publication of 2IQP study in Diabetes Care
- Tandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold Rating
- Tandem Diabetes assumed with an Outperform at Oppenheimer